Treprostinil Oral Inhalation Solution (TYVASO), Dry Powder Inhaler (TYVASO DPI), and Dry Powder Inhaler (YUTREPIA) for Pulmonary Hypertension (PH) associated with Interstitial Lung Disease (ILD) Criteria for Use August 2025

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the *PBM INTRAnet* site for further information.

Inclusion Criteria

All of the following criteria must be met.

- ☐ Care provided by a VA/ VA Community Care provider experienced in the management of PH
- ☐ Definitive, confirmed diagnosis of ILD^1 (e.g., diffuse parenchymal lung disease on chest CT)
- ☐ Definitive, confirmed diagnosis of WHO Group 3 PH by right-heart catheterization including hemodynamic diagnosis: mean pulmonary artery pressure of at least 25 mmHg, pulmonary capillary wedge pressure 15 mmHg or less, and pulmonary vascular resistance greater than 3 Wood units^2

Additional Inclusion Criteria

If applicable, the following criteria must be met.

- ☐ **For patients who would require more than one cartridge per dose using the DPI** (e.g., greater than 64 mcg of TYVASO or >106 mcg of YUTREPIA), the nebulized solution is preferred. The DPI should be reserved for patients with documented inability to use the nebulized product.^3

1. Examples of ILD include idiopathic interstitial pneumonia, combined pulmonary fibrosis and emphysema, connective tissue disease, and chronic hypersensitivity pneumonitis.
2. Hemodynamic definition based on exclusions from the INCREASE trial.
3. Cases should be adjudicated on an individual basis at the facility level.

Prepared: November 2023. Revised August 2025. Contact: Lisa Longo, Pharm.D., BCPS. National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)